XML 47 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)
 12 Months Ended
Dec. 31, 2019
Notes Tables  
Debt Securities, Available-for-sale [Table Text Block]
    December 31, 2019
    Amortized
Cost		   Accrued
Interest		   Gross
Unrealized
Gains		   Gross
Unrealized
Losses		   Estimated
Fair Value
Obligations of U.S. Government and its agencies   $
10,488
     $
50
     $
23
     $
-
     $
10,561
  
Corporate debt securities    
9,742
      
59
      
10
      
(1
 )    
9,810
  
Certificates of deposit    
1,669
      
7
      
7
      
-
      
1,683
  
Total investments   $
21,899
     $
116
     $
40
     $
(1
 )   $
22,054
  
    December 31, 2018
    Amortized
Cost		   Accrued
Interest		   Gross
Unrealized
Gains		   Gross
Unrealized
Losses		   Estimated
Fair Value
Obligations of U.S. Government and its agencies   $
50,613
     $
176
     $
15
     $
(131
 )   $
50,673
  
Corporate debt securities    
45,793
      
254
      
4
      
(171
 )    
45,880
  
Certificates of deposit    
3,559
      
14
      
-
      
(14
 )    
3,559
  
Total investments   $
99,965
     $
444
     $
19
     $
(316
 )   $
100,112
  
Available For Sale Securities Debt Maturities Fair Value [Table Text Block]
    2019   2018
Maturing in one year or less   $
22,054
     $
77,736
  
Maturing after one year through two years    
-
      
22,376
  
Total investments   $
22,054
     $
100,112
  
Schedule of Receivables from Collaborations [Table Text Block]
    December 31, 2019
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $
1,353
     $
15,023
     $
16,376
  
Shionogi & Co. Ltd.    
1,336
      
4
      
1,340
  
Green Cross Corporation    
2,924
      
8
      
2,932
  
Mundipharma International Holdings Limited    
56
      
-
      
56
  
Seqirus UK Limited    
1,091
      
351
      
1,442
  
Total receivables   $
6,760
     $
15,386
     $
22,146
  
    December 31, 2018
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $
-
     $
1,525
     $
1,525
  
Shionogi & Co. Ltd.    
854
      
-
      
854
  
Green Cross Corporation    
876
      
28
      
904
  
Mundipharma International Holdings Limited    
44
      
-
      
44
  
Seqirus UK Limited    
940
      
26
      
966
  
Total receivables   $
2,714
     $
1,579
     $
4,293
  
Schedule of Accrued Liabilities [Table Text Block]
    December 31,
    2019   2018
Compensation and benefits   $
6,190
     $
4,659
  
Development costs    
11,302
      
7,564
  
Inventory    
29
      
1,649
  
Professional fees    
326
      
118
  
Duties and taxes    
67
      
51
  
Other    
3,451
      
1,850
  
Total accrued expenses   $
21,365
     $
15,891
  
Disaggregation of Revenue [Table Text Block]
    2019   2018   2017
Product sales, net   $
17,533
     $
-
     $
1,501
  
Royalty revenue    
6,303
      
6,101
      
10,543
  
Collaborative and other research and development revenues:                        
U.S. Department of Health and Human Services    
4,898
      
2,552
      
4,608
  
Torii Pharmaceutical Co., Ltd.    
20,101
      
-
      
-
  
Shionogi & Co. Ltd.    
-
      
-
      
1,184
  
Seqirus UK Limited    
-
      
12,000
      
7,350
  
Total collaborative and other research and development revenues    
24,999
      
14,552
      
13,142
  
Total revenues   $
48,835
     $
20,653
     $
25,186